Top 5 Articles of the Week: March 2-7

To stay up-to-date with the latest dermatology news, sign up to receive oureNewsletters.

1. New Study Explores Benzoyl Peroxide-Related Adverse Event, Neoplasm Case Signals

Using data from the FDA’s Adverse Event Reporting System (FAERS), researchers identified a significant increase in reports of neoplasms, including skin and breast cancers, among BPO users. While the study does not establish causality, it aligns with growing concerns about benzene contamination in BPO products, which previous research has linked to increased cancer risks. The findings highlight the need for further investigation into the long-term safety of BPO-containing treatments, urging both consumers and healthcare providers to stay informed as regulatory bodies assess potential risks.

2. Almirall Showcases Therapeutic Innovations at AAD 2025

At the 2025 American Academy of Dermatology (AAD) Annual Meeting, Almirall showcased its commitment to advancing dermatological treatments through five scientific posters. Highlights included new data on tirbanibulin, reinforcing its efficacy and patient satisfaction in treating actinic keratosis (AK), and early-stage clinical findings on LAD191, a monoclonal antibody targeting IL-1RAP for immune-modulated skin diseases. The research underscores Almirall’s focus on patient-centered care, innovation in biologic therapies, and addressing unmet needs in dermatology.

3. The Environmental Cost of Conferences

The widespread distribution of cosmeceutical samples at large dermatology conferences, such as the EADV Congress, raises significant environmental concerns, particularly due to the excessive use of single-use plastics and the indiscriminate disposal of promotional items. Researchers highlight that these materials contribute to long-term environmental damage, necessitating sustainable solutions. Key recommendations include implementing green policies, establishing recycling stations, and encouraging delegates to return or request samples more responsibly. A shift toward digital sampling—using QR codes to request home-delivered samples—could also reduce waste while improving targeted marketing. Additionally, lifecycle analysis (LCA) can help optimize resource use and minimize the environmental impact of cosmeceutical production. By adopting these sustainable practices, stakeholders in the dermatology field can significantly reduce the ecological footprint of conferences while maintaining product accessibility.

4. “The Undetectable Era”: How Patients Are Shifting Towards More Natural-Looking Results at the Clinic

The “undetectable era” in aesthetics marks a shift toward subtle, natural-looking results where cosmetic procedures enhance beauty without being obvious. Kristy Hamilton, MD, FACS, a board-certified plastic surgeon, attributes this trend to social media influence, earlier interventions, and evolving patient preferences. Recent data from Allergan Aesthetics supports this, showing a decline in patients seeking dramatic changes and an increased desire for minimal yet effective wrinkle treatment. Social media platforms like Instagram and TikTok have played a key role in normalizing aesthetic enhancements, with influencers and celebrities sharing their experiences. Hamilton emphasizes a comprehensive approach to treatment, balancing surgical and non-surgical procedures to maintain natural results. Setting realistic patient expectations is crucial, with education, transparency, and gradual treatments fostering trust.

5. The Unprecedented Phase 1 Results of ET-02 for the Treatment of Androgenic Alopecia

Eirion Therapeutics recently announced promising results from its first-in-human trial of ET-02, a topical treatment for androgenic alopecia. The drug demonstrated a strong safety profile, with no adverse skin reactions, ocular irritation, or systemic effects observed. Remarkably, ET-02 showed unprecedented efficacy, with six times the hair growth compared to placebo after just four weeks—surpassing the results of 5% minoxidil at four months. Jon Edelson, MD, CEO of Eirion, explained that ET-02 takes a novel approach by addressing a fundamental defect in stem cell biology rather than simply stimulating hair follicles. By reactivating dormant stem cells, ET-02 aims to restore natural hair growth and potentially prevent hair loss altogether. This breakthrough positions ET-02 as a unique addition to the hair loss treatment landscape, offering new hope for those affected by androgenic alopecia.